CDKN2A and neoplasm: CDKN2A/B co‐mutations were significantly represented in tumours with STK11 (63%, 10/16, p = 0.024), KEAP1 (59%, 10/17, p = 0.045), and SPEN (90%, 9/10, p < 0.001) alterations, and in all tumours with MTAP alterations (100%, 16/16, p < 0.001).